- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05641714
The Reliability and Validity of the L-test in Patients With Multiple Sclerosis
Walking safely inside or outside is an important function in patients with Multiple Sclerosis (PwMS) that affects their daily life activity and participation. Loss of functional mobility is the major component of walking disorders in PwMS. Therefore, it is important to evaluate functional mobility.
Many functional mobility tests have been used for PwMS; however, these tests generally focus on walking speed and endurance. On the other hand, the L test, a variation of the timed up and go test (TUG), is a functional mobility measurement tool that extends the total walking distance to 20 meters and also requires the patients to turn both clockwise and counterclockwise.
Although L the test is an easy-to-use, short-term test method that evaluates higher-level components of functional mobility such as turns and transfers, to our knowledge, no study has systematically examined the reliability and validity of the L test in PwMS yet. In addition, the cut-off times that best discriminate PwMS from healthy people and fallers with non-fallers with Multiple Sclerosis (MS) have not been reported. Therefore, this study planned to investigate the reliability, validity, and discrimination of the L test in PwMS.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey
- Gazi University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age at least 18 years,
- Neurologist-diagnosed Multiple Sclerosis,
- Expanded Disability Status Scale (EDSS) score between 0-5,
- No MS exacerbation within the last 3 months,
- Use of stable medication in the last 3 months.
Exclusion Criteria:
- Having any vision, hearing, or perception problems that may affect the research results,
- Having an orthopedic problem that will prevent walking and standing
- Having a cardiovascular, pulmonary, or hormonal disorder
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
healthy controls
|
The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.
|
|
multiple sclerosis
Patients with Multiple Sclerosis
|
The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.
The test requires the individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.
In the test, the clinician measures the time taken to walk a distance of 10 m from a standing position.
Participants are asked to walk along a 14 m long walkway.
This test measures the distance (in m) that an individual is able to walk at a comfortable speed for 6 minutes.
Starting from a standing position, participants walk continuously around two pylons placed 30 m apart for 6 minutes.
The distance is recorded end of the test.
Each participant turns around in place in a standing position for both sides.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
L test
Time Frame: baseline
|
The L test evaluates functional mobility.
Higher durations indicate worse functional mobility performance.
|
baseline
|
|
L test-second assessment
Time Frame: the second assessment will be conducted after the seven days
|
The L test evaluates functional mobility.
Higher durations indicate worse functional mobility performance.
|
the second assessment will be conducted after the seven days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Timed Up and Go test
Time Frame: Baseline
|
Timed Up and Go test evaluates functional mobility.
Higher durations indicate worse functional mobility.
|
Baseline
|
|
10 meter walk test
Time Frame: Baseline
|
10 meter walk test is a performance measure used to assess walking speed in meters per second over a short distance.
It can be employed to determine functional mobility and gait.
|
Baseline
|
|
6 minute walk test
Time Frame: Baseline
|
This test measures the distance (in m) that an individual is able to walk at a comfortable speed for 6 minutes.
Starting from a standing position, participants walk continuously around two pylons placed 30 m apart for 6 minutes.
The distance is measured end of the test.
|
Baseline
|
|
the timed 360° turn test
Time Frame: Baseline
|
The timed 360° turn test is an easily administered, not time-consuming, and specific measurement tool to assess turning ability.
It measures the time taken for an individual to 360° turn around in a standing position.
The timed 360° turn test is also correlated with balance and functional mobility.
|
Baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Kim JS, Chu DY, Jeon HS. Reliability and validity of the L test in participants with chronic stroke. Physiotherapy. 2015 Jun;101(2):161-5. doi: 10.1016/j.physio.2014.09.003. Epub 2014 Oct 28.
- Deathe AB, Miller WC. The L test of functional mobility: measurement properties of a modified version of the timed "up & go" test designed for people with lower-limb amputations. Phys Ther. 2005 Jul;85(7):626-35.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-MS-L-Test-reliability
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; University of Copenhagen and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
Clinical Trials on L test
-
Hikari Dx, Inc.Timewell Medical Co., Ltd.CompletedAcute Kidney Injury | Contrast-induced NephropathyUnited States
-
Mayo ClinicRecruiting
-
Universidade Estadual Paulista Júlio de Mesquita...UnknownTooth Loss | Recession, GingivalBrazil
-
University of ZurichActive, not recruitingPulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Vascular DiseaseSwitzerland
-
AEterna ZentarisCompletedDiagnosis of Adult Growth Hormone Deficiency (AGDH)United States
-
Belfast Health and Social Care TrustAraim Pharmaceuticals, Inc.TerminatedDiabetic Macular OedemaUnited Kingdom
-
University of GuadalajaraUnknownBody Weight ChangesMexico
-
University of ManitobaMicropharma LimitedCompleted
-
Juliano CasonattoUnknown